Mesenchymal stem cells: Are we ready for clinical application in transplantation and tissue regeneration?

Frontiers in Immunology

Volumn 4, Issue JUN, 2013, Pages

  Hoogduijn, Martin J ^a   Dor, Frank J M F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1;

APOPTOSIS; CELL PROLIFERATION; EDITORIAL; GENE EXPRESSION; HUMAN; KIDNEY TRANSPLANTATION; LIVER DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; REGULATORY T LYMPHOCYTE; TISSUE REGENERATION; WOUND HEALING;

EID: 84883788738     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00144     Document Type: Editorial

References (12)

1. Ancans, J. (2012). Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development. Front. Immunol. 3:253. doi:10.3389/fimmu.2012.00253
2. Chen, J. S., Wong, V. W., and Gurtner, G. C. (2012). Therapeutic potential of bone marrow-derived mesenchymal stem cells for cutaneous wound healing. Front. Immunol. 3:192. doi:10.3389/fimmu.2012.00192
3. Christ, B., and Stock, P. (2012). Mesenchymal stem cell-derived hepatocytes for functional liver replacement. Front. Immunol. 3:168. doi:10.3389/fimmu.2012.00168
4. de Vries, D. K., Schaapherder, A. F., and Reinders, M. E. (2012). Mesenchymal stromal cells in renal ischemia/reperfusion injury. Front. Immunol. 3:162. doi:10.3389/fimmu.2012.00162
5. Delarosa, O., Dalemans, W., and Lombardo, E. (2012). Toll-like receptors as modulators of mesenchymal stem cells. Front. Immunol. 3:182. doi:10.3389/fimmu.2012.00182
6. Eggenhofer, E., Benseler, V., Kroemer, A., Popp, F. C., Geissler, E. K., Schlitt, H. J., et al. (2012). Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front. Immunol. 3:297. doi:10.3389/fimmu.2012.00297
7. Engela, A. U., Baan, C. C., Dor, F. J., Weimar, W., and Hoogduijn, M. J. (2012). On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. Front. Immunol. 3:126. doi:10.3389/fimmu.2012.00126
8. Franquesa, M., Hoogduijn, M. J., Bestard, O., and Grinyo, J. M. (2012). Immunomodulatory effect of mesenchymal stem cells on B cells. Front. Immunol. 3:212. doi:10.3389/fimmu.2012.00212
9. Leijs, M. J., Van Buul, G. M., Lubberts, E., Bos, P. K., Verhaar, J. A., Hoogduijn, M. J., et al. (2012). Effect of arthritic synovial fluids on the expression of immunomodulatory factors by mesenchymal stem cells: an explorative in vitro study. Front. Immunol. 3:231. doi:10.3389/fimmu.2012.00231
10. Seifert, M., Stolk, M., Polenz, D., and Volk, H. D. (2012). Detrimental effects of rat mesenchymal stromal cell pre-treatment in a model of acute kidney rejection. Front. Immunol. 3:202. doi:10.3389/fimmu.2012.00202
11. Vaes, B., Van't Hof, W., Deans, R., and Pinxteren, J. (2012). Application of multistem(R) allogeneic cells for immunomodulatory therapy: clinical progress and pre-clinical challenges in prophylaxis for graft versus host disease. Front. Immunol. 3:345. doi:10.3389/fimmu.2012.00345
12. Zinocker, S., and Vaage, J. T. (2012). Rat mesenchymal stromal cells inhibit T cell proliferation but not cytokine production through inducible nitric oxide synthase. Front. Immunol. 3:62. doi:10.3389/fimmu.2012.00062